Opendata, web and dolomites

ScleroTest SIGNED

A rapid and cost-effective point-of-care diagnostic kit able to predict treatment response for appropriate Multiple Sclerosis management

Total Cost €


EC-Contrib. €






 ScleroTest project word cloud

Explore the words cloud of the ScleroTest project. It provides you a very rough idea of what is the project "ScleroTest" about.

virus    biotechnology    2022    unmet    outcomes    feasibility    properly    chronic    scalability    10    issue    therapy    adults    neurologists    implantation    15    savings    immunomodulatory    mainly    lack    absence    medicine    poc    competitive    foresees    diseases    microbiota    clinical    accurate    plus    sclerosis    predictive    multiple    33    company    alternatives    accumulated    public    predicting    net    cheaper    fast    cagr    resonance    finalize    ca    acute    therapies    launch    opportunity    plan    invasive    substantial    worldwide    ing    02    health    predict    ms    diagnostic    globally    performance    women    commercial    successful    profiling    lt    correct    market    socioeconomic    competition    patient    central    biomarkers    25    rapid    men    pcr    point    18    prevalence    million    business    people    routine    biomarker    quick    magnetic    therapeutic    incidence    times    personalized    bioithas    profit    perform    prompt    young    24    patients    2026    inflammatory    58    annual    secure    disease    first    financial    jc    avenues    tool    sclerotest    autoimmune    nervous    care    added    cure    gut    analyzing    treatment    fruitful    technological   

Project "ScleroTest" data sheet

The following table provides information about the project.


Organization address
postcode: 3430
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOITHAS SL ES (ONIL ALICANTE) coordinator 50˙000.00


 Project objective

Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system currently affecting about 2.5 million people worldwide (mainly young adults, three times more women than men). There is no cure and therapies do not properly work in all patients. Personalized medicine is needed but we lack predictive biomarkers for treatment response to secure prompt and early treatment and the best clinical outcomes for each patient. Thus, MS represents a major public health issue with a substantial socioeconomic impact (€15.5 B annual costs in Europe). Bioithas is a biotechnology company in the field of health developing new diagnostic and therapeutic targets for autoimmune and inflammatory diseases. In response to the unmet need, it is focused on developing the first-ever gut microbiota based biomarker for predicting MS treatment response. ScleroTest, a quick point-of-care (PoC) diagnostic tool, will allow immunomodulatory profiling of patients to predict treatment response. It is a non-invasive, accurate (PCR performance), rapid (results in <24 h) and cost-competitive test (€25 test, ca. 58 % cheaper than magnetic resonance and JC virus alternatives). ScleroTest implantation in routine practice will face current MS management problems resulting on added value for patients, neurologists and health systems by allowing fast and correct therapy choice, better clinical outcomes and cost-savings. ScleroTest scalability will also open new avenues for personalized therapy in other diseases. Due to ScleroTest´s cost-competitive features plus the absence of real competition, the increasing MS prevalence and incidence globally and the growing PoC market (CAGR 10%, €33 B by 2022), Bioithas foresees ScleroTest as a fruitful business opportunity (accumulated net profit ca. €18.02 M, 2022-2026). To secure the successful market launch, we will perform a feasibility study analyzing technological, commercial and financial aspects to finalize our business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SCLEROTEST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SCLEROTEST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More